223 related articles for article (PubMed ID: 26289547)
21. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
Pablos-Mendez A; Gowda DK; Frieden TR
Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
[TBL] [Abstract][Full Text] [Related]
22. Multi-drug resistant Mycobacterium tuberculosis complex genetic diversity and clues on recent transmission in Punjab, Pakistan.
Yasmin M; Gomgnimbou MK; Siddiqui RT; Refrégier G; Sola C
Infect Genet Evol; 2014 Oct; 27():6-14. PubMed ID: 24981519
[TBL] [Abstract][Full Text] [Related]
23. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment.
Ormerod LP
Br Med Bull; 2005; 73-74():17-24. PubMed ID: 15956357
[TBL] [Abstract][Full Text] [Related]
24. MDR-TB--its characteristics and control in Asia-Pacific rim symposium in USJCMSP 10th international conference on emerging infectious diseases in the Pacific rim.
Mori T
Tuberculosis (Edinb); 2007 Aug; 87 Suppl 1():S5-9. PubMed ID: 17588496
[TBL] [Abstract][Full Text] [Related]
25. Nanocarrier-based interventions for the management of MDR/XDR-TB.
Mustafa S; Pai RS; Singh G; Kusum Devi V
J Drug Target; 2015 May; 23(4):287-304. PubMed ID: 25766078
[TBL] [Abstract][Full Text] [Related]
26. [Management of multidrug-resistant tuberculosis].
Tritar F; Daghfous H; Ben Saad S; Slim-Saidi L
Rev Pneumol Clin; 2015; 71(2-3):130-9. PubMed ID: 25153927
[TBL] [Abstract][Full Text] [Related]
27. Cost of multi drug resistance tuberculosis in Germany.
Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
[TBL] [Abstract][Full Text] [Related]
28. Management of multidrug resistant tuberculosis.
Daley CL; Caminero JA
Semin Respir Crit Care Med; 2013 Feb; 34(1):44-59. PubMed ID: 23460005
[TBL] [Abstract][Full Text] [Related]
29. The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains.
McBryde ES; Meehan MT; Doan TN; Ragonnet R; Marais BJ; Guernier V; Trauer JM
Int J Infect Dis; 2017 Mar; 56():14-20. PubMed ID: 28163165
[TBL] [Abstract][Full Text] [Related]
30. Tuberculosis in Europe: a problem of drug resistance or much more?
Carvalho AC; Migliori GB; Cirillo DM
Expert Rev Respir Med; 2010 Apr; 4(2):189-200. PubMed ID: 20406085
[TBL] [Abstract][Full Text] [Related]
31. Drug-resistant tuberculosis in Cuba. Results of the three global projects.
Montoro E; Lemus D; Echemendía M; Armas L; González-Ochoa E; Llanes MJ; Valdivia JA
Tuberculosis (Edinb); 2006; 86(3-4):319-23. PubMed ID: 16569512
[TBL] [Abstract][Full Text] [Related]
32. Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives.
Migliori GB; Centis R; Lange C; Richardson MD; Sotgiu G
Curr Opin Pulm Med; 2010 May; 16(3):171-9. PubMed ID: 20134324
[TBL] [Abstract][Full Text] [Related]
33. The making of a public health problem: multi-drug resistant tuberculosis in India.
Engel NC
Health Policy Plan; 2013 Jul; 28(4):375-85. PubMed ID: 22865835
[TBL] [Abstract][Full Text] [Related]
34. The re-emergence of tuberculosis.
Porter JD; McAdam KP
Annu Rev Public Health; 1994; 15():303-23. PubMed ID: 8054087
[TBL] [Abstract][Full Text] [Related]
35. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China.
Zhang Z; Pang Y; Wang Y; Liu C; Zhao Y
Int J Antimicrob Agents; 2014 Mar; 43(3):231-5. PubMed ID: 24439458
[TBL] [Abstract][Full Text] [Related]
36. Isolation of Mycobacterium tuberculosis from sputum of tribal, non-tribal pulmonary tuberculosis patients of Andaman & Nicobar islands by conventional culture method and assessment of first line anti-tuberculosis drug susceptibility patterns.
Mandal A; Parthasarathy G; Burma SP; Sugunan AP; Vijayachari P
Indian J Tuberc; 2015 Jan; 62(1):23-8. PubMed ID: 25857562
[TBL] [Abstract][Full Text] [Related]
37. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
38. Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting.
Catho G; Couraud S; Grard S; Bouaziz A; Sénéchal A; Valour F; Perpoint T; Braun E; Biron F; Ferry T; Chidiac C; Freymond N; Perrot E; Souquet PJ; Maury JM; Tronc F; Veziris N; Lina G; Dumitrescu O; Ader F;
Clin Microbiol Infect; 2015 May; 21(5):472.e7-10. PubMed ID: 25708551
[TBL] [Abstract][Full Text] [Related]
39. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness.
Cohen T; Murray M
Nat Med; 2004 Oct; 10(10):1117-21. PubMed ID: 15378056
[TBL] [Abstract][Full Text] [Related]
40. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa.
Mlambo CK; Warren RM; Poswa X; Victor TC; Duse AG; Marais E
Int J Tuberc Lung Dis; 2008 Jan; 12(1):99-104. PubMed ID: 18173885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
